{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:30:52Z","timestamp":1794576652297,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005609","name":"Turun Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011797","name":"Turun Yliopistollinen Keskussairaala","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011797","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.eururo.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T20:11:59Z","timestamp":1679083919000},"page":"405-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":330,"title":["Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE\u00a0V2)"],"prefix":"10.1016","volume":"83","author":[{"given":"Robert","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik L.","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang Peter","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2023.02.002_b0005","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2023.02.002_b0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18 F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.02.002_b0015","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2023.02.002_b0020","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2023.02.002_b0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0030","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2023.02.002_b0035","first-page":"1644","article-title":"The PRIMARY score: using intra-prostatic PSMA PET\/CT patterns to optimise prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0040","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.02.002_b0045","unstructured":"SEER database. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"10.1016\/j.eururo.2023.02.002_b0050","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2967\/jnumed.119.233817","article-title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria","volume":"61","author":"Fanti","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0055","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2967\/jnumed.115.169243","article-title":"Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer","volume":"57","author":"Rahbar","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0065","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.02.002_b0070","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2967\/jnumed.121.262398","volume":"63","author":"Sonni","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0075","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2967\/jnumed.116.172627","article-title":"68 Ga-PSMA PET\/CT detects the location and extent of primary prostate cancer","volume":"57","author":"Fendler","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0080","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1148\/radiol.2019190687","article-title":"Diagnostic accuracy of multiparametric MRI versus 68Ga-PSMA-11 PET\/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer","volume":"293","author":"Muehlematter","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2023.02.002_b0085","series-title":"AJCC cancer staging manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.eururo.2023.02.002_b0090","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0095","first-page":"746","article-title":"Repeatability of 68 Ga-PSMA-HBED-CC PET\/CT-derived total molecular tumor volume","volume":"63","author":"Seifert","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0100","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2967\/jnumed.119.236083","article-title":"Quantitative test-retest measurement of 68Ga-PSMA-HBED-CC in tumor and normal tissue","volume":"61","author":"Pollard","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0105","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","article-title":"Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer","volume":"61","author":"Seifert","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0110","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2023.02.002_b0115","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.7150\/thno.60222","article-title":"Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy","volume":"11","author":"Seifert","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.eururo.2023.02.002_b0120","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using 68 Ga-PSMA ligand PET in patients undergoing 177 Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","author":"Grubm\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2023.02.002_b0125","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","article-title":"qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68 Ga-PSMA11 PET\/CT","volume":"60","author":"Gafita","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2967\/jnumed.120.261863","article-title":"aPROMISE: a novel automated-PROMISE platform to standardize evaluation of tumor burden in 18 F-DCFPyL (PSMA) images of veterans with prostate cancer","volume":"63","author":"Nickols","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0135","first-page":"857","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"61","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2023.02.002_b0140","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2023.02.002_b0145","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2967\/jnumed.117.195255","article-title":"Proposal for a structured reporting system for prostate-specific membrane antigen\u2013targeted PET imaging: PSMA-RADS version 1.0","volume":"59","author":"Rowe","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0155","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2967\/jnumed.120.261834","article-title":"Oliver Sartor talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler about FDA approval of PSMA","volume":"62","author":"Sartor","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0160","unstructured":"PSMA TNM Stager. https:\/\/www.tnm-stager.com."},{"key":"10.1016\/j.eururo.2023.02.002_b0165","unstructured":"Eiber M. ePROMISE (free academic tool for Windows and Mac, to be requested by email: matthias.eiber@tum.de)."},{"key":"10.1016\/j.eururo.2023.02.002_b0170","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.02.002_b0175","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2967\/jnumed.119.235028","article-title":"3-year freedom from progression after 68Ga-PSMA PET\/CT-Triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial","volume":"61","author":"Emmett","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0180","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2967\/jnumed.119.233429","article-title":"Additional local therapy for liver metastases in patients with metastatic castration-resistant prostate cancer receiving systemic PSMA-targeted therapy","volume":"61","author":"Seifert","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0185","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/ERC-18-0226","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","author":"Bakht","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.eururo.2023.02.002_b0190","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.7150\/thno.35759","article-title":"Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177 Lu-PSMA-617","volume":"9","author":"Kessel","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.eururo.2023.02.002_b0195","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2023.02.002_b0200","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.euo.2018.11.007","article-title":"Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy","volume":"2","author":"Thang","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2023.02.002_b0205","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2967\/jnumed.119.231431","article-title":"Response prediction of 177 Lu-PSMA-617 radioligand therapy using prostate-specific antigen, chromogranin A, and lactate dehydrogenase","volume":"61","author":"Rathke","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0210","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.2967\/jnumed.121.263441","article-title":"Outcome of patients with PSMA-PET\/CT screen failure by VISION criteria and treated with 177 Lu-PSMA therapy: a multicenter retrospective analysis","volume":"63","author":"Hotta","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0215","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1200\/JCO.2022.40.16_suppl.5043","article-title":"PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: an international multicenter retrospective study","volume":"40","author":"Hotta","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.02.002_b0220","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.2967\/jnumed.121.261982","article-title":"Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort","volume":"62","author":"Calais","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0225","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2967\/jnumed.120.260836","article-title":"Assessing response to 177 Lu-PSMA radioligand therapy using modified PSMA PET progression criteria","volume":"62","author":"Michalski","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.02.002_b0230","doi-asserted-by":"crossref","unstructured":"Kind F, Eder A-C, Jilg CA, et al. Prognostic value of tumor volume assessment on PSMA PET after 177 Lu-PSMA radioligand therapy evaluated by PSMA PET\/CT consensus statement and RECIP 1.0. J Nucl Med. In press. https:\/\/doi.org\/10.2967\/jnumed.122.264489.","DOI":"10.2967\/jnumed.122.264489"},{"key":"10.1016\/j.eururo.2023.02.002_b0235","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2967\/jnumed.121.263638","article-title":"Why we did what we did: PSMA PET\/CT selection criteria for the VISION trial","volume":"63","author":"Kuo","year":"2022","journal-title":"J Nucl Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823025745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823025745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:13:19Z","timestamp":1759583599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283823025745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0302283823025745"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE\u00a0V2)","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}